GlaxoSmithKline's Nucala given positive opinion by EU's CHMP

(Alliance News) - GlaxoSmithKline PLC on Friday said the European Medicines Agency's Committee ...

Alliance News 17 September, 2021 | 2:05PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - GlaxoSmithKline PLC on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has given positive opinions for Nucala, or mepolizumab, being used in three eosinophil-driven diseases.

The three diseases were hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis and chronic rhinosinusitis with nasal polyps. The positive opinion is one of the final steps in the marketing authorisation procedure before approval by the European Commission.

The opinions were based on data from pivotal studies investigating the role of targeting IL-5 inhibition with Nucala in these diseases. Eosinophil-driven diseases are inflammatory conditions associated with elevated levels of eosinophils, a type of white blood cell.

"We are pleased with the CHMP's positive opinions as there are currently limited targeted treatment options available for patients in Europe with eosinophil-driven disease. If approved, mepolizumab would be the first targeted treatment available for use in four of these diseases and would further reinforce its role in targeting the underlying cause of inflammation," said Senior Vice President of Development Christopher Corsico.

Shares in GlaxoSmithKline were marginally higher at 1,395.20 pence on Friday in London.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,638.00 GBX -0.15

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures